title: [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
abstract: In a milnacipran study, ninety-six patients with major depressive disorder were treated with milnacipran, 50-100 mg/day, for 6 weeks. Severity of depression was assessed with the Montgomery and Asberg Depression Rating Scale. The purpose of this study was to determine whether norepinephrine transporter (NET) gene and serotonin transporter (5-HTT) gene polymorphisms are associated with the antidepressant response to milnacipran, a serotonin and norepinephrine reuptake inhibitor. Eighty patients completed the study. The presence of the T allele of the NET T-182C polymorphism was associated with a superior antidepressant response. In contrast, no influence of 5-HTTLPR (5-HTT linked polymorphic region) on the antidepressant response to milnacipran was detected. The results suggest that NET but not 5-HTT polymorphisms in part determine the antidepressant response to milnacipran. In a fluvoxamine study, sixty-six patients with major depressive disorder were treated with fluvoxamine, 100-200 mg/day, for 6 weeks. The authors investigated whether 5-HTTLPR was associated with the antidepressant response to fluvoxamine, a selective serotonin reuptake inhibitor. Fifty-seven patients completed the study. The short (s) allele frequency was significantly higher in the responsive individuals than in the nonresponsive ones. The results suggest that fluvoxamine is not less effective in depressive patients carrying the s allele than in those carrying the long (1) allele and it is not less effective in Japanese than in Caucasians.
authors.affiliation: Department of Neuropsychiatry, St Marianna Medical University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, 216-8511 Japan. h5higuchi@marianna-u.ac.jp
authors.forename: Hisashi
authors.initials: H
authors.lastname: Higuchi
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D016666:Fluvoxamine / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic / Q000235:genetics; D044469:Racial Groups; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D003521:Cyclopropanes; D016666:Fluvoxamine; D000078764:Milnacipran; D050484:Norepinephrine Plasma Membrane Transport Proteins; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors